Bacteria building resistance to moxifloxacin

Article

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers.

Although moxifloxacin has excellent antibacterial coverage, there is an emergence of a resistance to it in bacteria isolated from corneal ulcers, according to Gita Sathpathy and co-workers at the All India Institute of Medical Sciences, New Dehli, India.

The records of 934 consecutive cases of bacterial corneal ulcers were retrospectively reviewed and culture and antibiotic sensitivity reports of corneal scrapings were analysed. Recorded parameters included age, sex, organism isolated and sensitivity, using Kirby-Bauer disc-diffusion, to moxifloxacin. The bacterial isolates that were resistant to moxifloxacin were examined in detail and their antibiotic sensitivity to other drugs was studied.

Of the 934 bacterial isolates, 913 (97.5%) were sensitive to moxifloxacin and 21 (2.25%) were found to be resistant. Of the 21 resistant isolates, eight were Staphylococcus albus, eight were Pseudomonas, two were Streptococcus viridians, one was Streptococcus pneumoniae, one was Staphylococcus aureus and one was E. coli. Of the eight Pseudomonas cases, six were found to be sensitive to polymyxin and five sensitive to amikacin. Out of the eight Staphylococcus, seven were sensitive to vancomycin.

The emergence of a resistance to moxifloxacin in bacteria isolated from corneal ulcers, indicates that the drug should not be used indiscriminately.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.